NEW YORK (GenomeWeb News) – Qiagen today announced that it is collaborating with the Chittaranjan National Cancer Institute to establish a large-scale cervical screening program in Kolkata, India, which will utilize Qiagen's Hybrid Capture II human papillomavirus test.

Qiagen will provide the tests and CNCI will conduct the screening and provide appropriate treatment as needed. Women will also be screened using visual inspection with acetic acid, as per the Indian National Guidelines for Cervical Screening, said Qiagen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.